Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scholar Rock, LLC

http://www.scholarrock.com

Latest From Scholar Rock, LLC

Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME

Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.

Regulation Research & Development

Scholar Rock Sees Phase III Path For SMA Drug

While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.

Research & Development Neurology

Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp

Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.

Companies Commercial

The SMA Market: Assessing The Unknowns

The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.

Innovation Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Scholar Rock, Inc.
UsernamePublicRestriction

Register